Trustmark National Bank Trust Department trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 10.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 23,133 shares of the medical research company's stock after selling 2,811 shares during the quarter. Trustmark National Bank Trust Department's holdings in Amgen were worth $6,029,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently bought and sold shares of AMGN. Vanguard Group Inc. grew its position in shares of Amgen by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 52,721,795 shares of the medical research company's stock worth $13,741,409,000 after acquiring an additional 339,522 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Amgen by 25.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock valued at $3,441,909,000 after purchasing an additional 2,672,975 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Amgen by 2.9% during the fourth quarter. Geode Capital Management LLC now owns 12,475,032 shares of the medical research company's stock worth $3,245,881,000 after purchasing an additional 352,143 shares during the period. Norges Bank bought a new position in shares of Amgen in the 4th quarter worth about $1,541,991,000. Finally, Invesco Ltd. grew its position in shares of Amgen by 7.5% during the 4th quarter. Invesco Ltd. now owns 3,887,248 shares of the medical research company's stock valued at $1,013,172,000 after buying an additional 270,135 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.
Insider Transactions at Amgen
In other news, EVP Jonathan P. Graham sold 25,045 shares of Amgen stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the sale, the executive vice president now directly owns 28,987 shares in the company, valued at $8,496,669.44. The trade was a 46.35 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the firm's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 69,341 shares of company stock valued at $20,644,335 over the last quarter. Company insiders own 0.69% of the company's stock.
Amgen Trading Down 1.9 %
Shares of Amgen stock traded down $5.35 on Friday, reaching $277.29. 4,371,822 shares of the company were exchanged, compared to its average volume of 2,796,109. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The firm has a market capitalization of $149.09 billion, a price-to-earnings ratio of 36.73, a price-to-earnings-growth ratio of 2.63 and a beta of 0.59. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The stock has a fifty day moving average price of $303.04 and a 200-day moving average price of $294.22.
Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, analysts expect that Amgen Inc. will post 20.62 EPS for the current year.
Amgen Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.43%. Amgen's payout ratio is currently 126.09%.
Analyst Ratings Changes
AMGN has been the subject of a number of research reports. Piper Sandler lifted their target price on Amgen from $310.00 to $329.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. StockNews.com lowered Amgen from a "strong-buy" rating to a "buy" rating in a research report on Thursday. Royal Bank of Canada restated an "outperform" rating and set a $324.00 price target on shares of Amgen in a research report on Friday, January 24th. Wells Fargo & Company restated an "equal weight" rating on shares of Amgen in a research report on Wednesday, February 5th. Finally, Piper Sandler Companies reissued an "overweight" rating and issued a $310.00 price objective on shares of Amgen in a report on Thursday, January 2nd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $314.91.
View Our Latest Report on AMGN
Amgen Profile
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Further Reading
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
